(MedPage Today) — Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson’s disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
At 96 weeks, mean Movement Disorder Society…
Source link : https://www.medpagetoday.com/neurology/parkinsonsdisease/114113
Author :
Publish date : 2025-02-06 20:35:02
Copyright for syndicated content belongs to the linked Source.
